Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 7/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.31 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24286081 | 0.81 | PIM1 (0.30) | — | |
| SCHEMBL24286014 | 0.80 | USP7 (0.32) | ALDH1A1 | |
| SCHEMBL24285859 | 0.78 | CA12 (0.45) | MTORPIK3CD | |
| SCHEMBL29537477 | 0.77 | LRRK2 (0.37) | — | |
| SCHEMBL24285946 | 0.77 | LRRK2 (0.37) | — | |
| SCHEMBL24286072 | 0.74 | PIM1 (0.34) | ALDH1A1TGFBR1TGFBR2MTOR | |
| SCHEMBL24285948 | 0.72 | MAP3K14 (0.43) | ALDH1A1CYP3A4 | |
| SCHEMBL24286245 | 0.71 | MET (0.44) | ALDH1A1CHEK1 | |
| SCHEMBL24285974 | 0.70 | RIPK1 (0.50) | CHEK1MTORPIK3CD | |
| SCHEMBL24285831 | 0.70 | LRRK2 (0.48) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | 1ST Biotherapeutics, Inc. (KR) | 2023-09-05 | — | — | US | disclosed |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744824-B2 | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | NLRP3, NLRP1, KCNJ2 | TDO2 3217/4885ALDH1A1 1057/4885ATR 2073/4885 |
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | TDO2 3217/4885ALDH1A1 1057/4885ATR 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.